Related Experiment Video
Updated: Jun 3, 2026
A Protocol for Roux-en-Y Gastric Bypass in Rats using Linear Staplers
Published on: August 21, 2021
PEG-rhGH therapy for small for gestational age rats and effects on their metabolic parameters
Yanping Xu1, Huang Ke, Li Liang
1Department of Endocrinology, The Children's Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Aims:
To determine whether administration of long-acting polyethylene glycol moiety covalently linked to recombinant human growth hormone (PEG-rhGH) can be efficacious in the treatment of small for gestational age (SGA) rats and to characterize its effects on metabolic parameters.
Methods:
20 pregnant rats were randomly divided into undernourished and standard nourished groups. SGA or appropriate for gestational age (AGA) offspring from each were then randomly assigned to receive either PEG-rhGH or normal saline (NS). Once-weekly subcutaneous injections of PEG-rhGH (2 μg/g/week) were administered starting at 21-42 days. Glycometabolism, blood pressure (BP), hormone and biochemical levels were analyzed at 21, 42 and 70 days.
Results:
SGA rats at 21 days were lighter and shorter than AGAs (34.77 ± 2.11 vs. 48.83 ± 1.78 g, 10.42 ± 0.22 vs. 12.99 ± 0.17 cm, p < 0.05). At 42 days, SGA animals experienced a greater body weight gain. BP was higher in NS-treated SGA than in the AGA group at 70 days (138.16 ± 3.02 vs. 112.26 ± 5.42 mm Hg, p < 0.05). Meanwhile, NS-treated SGA exhibited higher glucose levels at 60 and 90 min than the AGA groups. No differences in hormone levels between the SGA and AGA groups were found at the end of PEG-rhGH treatment.
Conclusion:
These data suggest that PEG-rhGH treatment does not increase the risk of developing metabolic syndrome in adolescent aged rats.
